Glofitamab, Ibrutinib and Obinutuzumab for Untreated Mantle Cell Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mantle cell lymphoma that has not been treated before.
- You must be 18 to 64 years old with high-risk disease features, or 65 or older.
- You must have a tumor that can be seen on scans.
- You must be up and about for at least half the day (ECOG score 0-2).
- You must have adequate liver, kidney, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This study tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) to see if it is safe and effective for people with a fast-growing or hard-to-treat type of mantle cell lymphoma. If you have high-risk features, this therapy might be an option.
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
This trial tests a combination of three medications (zanubrutinib, obinutuzumab, and sonrotoclax) for people with mantle cell lymphoma, a type of blood cancer. The goal is to see if this combination is safe and effective, and it may be an option for people who are older or have health issues that make a stem cell transplant too risky.
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.